Equities Analysts Issue Forecasts for AXSM FY2024 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, January 13th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($4.04) for the year, up from their prior estimate of ($4.13). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.61) per share. William Blair also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($0.84) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at ($1.62) EPS and FY2026 earnings at $4.74 EPS.

Several other research firms also recently issued reports on AXSM. Royal Bank of Canada upped their price objective on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday, January 13th. Robert W. Baird boosted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Tuesday, December 31st. Finally, Truist Financial lifted their price target on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $130.69.

Axsome Therapeutics Trading Down 1.9 %

Shares of AXSM stock opened at $91.93 on Thursday. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $105.00. The company has a market cap of $4.45 billion, a PE ratio of -14.08 and a beta of 1.04. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The business’s 50 day moving average is $92.27 and its two-hundred day moving average is $89.39.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same quarter in the previous year, the firm earned ($1.32) earnings per share.

Institutional Investors Weigh In On Axsome Therapeutics

Institutional investors have recently bought and sold shares of the business. WINTON GROUP Ltd lifted its holdings in shares of Axsome Therapeutics by 156.6% during the 2nd quarter. WINTON GROUP Ltd now owns 8,823 shares of the company’s stock worth $710,000 after acquiring an additional 5,385 shares during the period. XTX Topco Ltd lifted its stake in Axsome Therapeutics by 177.9% during the second quarter. XTX Topco Ltd now owns 11,205 shares of the company’s stock worth $902,000 after purchasing an additional 7,173 shares during the period. Sei Investments Co. boosted its holdings in Axsome Therapeutics by 13.9% during the second quarter. Sei Investments Co. now owns 40,624 shares of the company’s stock valued at $3,270,000 after purchasing an additional 4,970 shares in the last quarter. HighVista Strategies LLC grew its stake in shares of Axsome Therapeutics by 28.2% in the 2nd quarter. HighVista Strategies LLC now owns 62,192 shares of the company’s stock valued at $5,006,000 after purchasing an additional 13,665 shares during the period. Finally, Hood River Capital Management LLC raised its holdings in shares of Axsome Therapeutics by 5.4% in the 2nd quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock worth $44,200,000 after buying an additional 28,316 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.